Ivantis, a US-based eye disease company has raised $27m in its series B round from a consortium led by corporate venturing unit Ascension Health Ventures as a new investor.
Venture capital firms New Enterprise Associates (NEA) and Delphi Ventures, and MemorialCare Innovation Fund also participated in the round.
In June 2011, Ivantis raised $17m from NEA and Delphi, having been incubated at NEA in 2007.